Capital World Investors Holds 22M Shares of Vertex Pharma

TL;DR

**Capital World Investors still owns over 22 million shares of Vertex Pharma, showing strong institutional backing.**

AI Summary

Capital World Investors, a major institutional investor, filed an amended SC 13G/A on February 9, 2024, disclosing its ownership in Vertex Pharmaceuticals Inc. As of December 29, 2023, Capital World Investors beneficially owned 22,080,207 shares of Vertex's common stock, representing a significant stake. This filing indicates a substantial, long-term institutional commitment to Vertex, which can be a positive signal for current and prospective shareholders, suggesting confidence in the company's future prospects.

Why It Matters

This filing shows that a large, influential institutional investor, Capital World Investors, maintains a significant stake in Vertex Pharmaceuticals, signaling their continued confidence in the company's long-term value.

Risk Assessment

Risk Level: low — This filing indicates stable institutional ownership, which generally reduces volatility and provides a foundation of support for the stock.

Analyst Insight

A smart investor would view this continued significant institutional ownership by Capital World Investors as a positive signal, suggesting long-term confidence in Vertex Pharmaceuticals, and might consider it as a factor in their own investment decisions.

Key Numbers

• 22,080,207 — Shares Beneficially Owned (This is the total number of Vertex Pharmaceuticals shares Capital World Investors reported owning as of December 29, 2023.)
• 22,009,491 — Sole Voting Power Shares (This represents the number of shares over which Capital World Investors has the sole right to vote.)
• 22,080,207 — Sole Dispositive Power Shares (This indicates the number of shares over which Capital World Investors has the sole right to sell or dispose of.)

Key Players & Entities

• Capital World Investors (company) — the reporting person and institutional investor
• Vertex Pharmaceuticals Inc. (company) — the subject company whose shares are being reported
• 22,080,207 (dollar_amount) — the aggregate number of shares beneficially owned by Capital World Investors
• December 29, 2023 (date) — the date of the event requiring the filing
• February 9, 2024 (date) — the filing date of the SC 13G/A

Forward-Looking Statements

• Capital World Investors will likely maintain a significant stake in Vertex Pharmaceuticals for the foreseeable future. (Capital World Investors) — high confidence, target: December 29, 2024
• The substantial institutional ownership by Capital World Investors will continue to provide a degree of stability to Vertex Pharmaceuticals' stock price. (Vertex Pharmaceuticals Inc.) — medium confidence, target: June 30, 2024

FAQ

Filing Documents

• SEC13G_Filing.htm (SC 13G/A) — 16KB
• 0001422848-24-000255.txt ( ) — 18KB

From the Filing

SC 13G/A 1 SEC13G_Filing.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 ) * Vertex Pharmaceuticals Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 92532F100 (CUSIP Number) December 29, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [X] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes.) CUSIP No. 92532F100 1. NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY) Capital World Investors 95-1411037 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [ ] 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Delaware NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 22,009,491 6. SHARED VOTING POWER 0 7. SOLE DISPOSITIVE POWER 22,080,207 8. SHARED DISPOSITIVE POWER 0 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 22,080,207 Beneficial ownership disclaimed pursuant to Rule 13d-4 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES [ ] 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 8.6% 12. TYPE OF REPORTING PERSON IA Item 1. (a) Name of Issuer Vertex Pharmaceuticals Inc. (b) Address of Issuer's Principal Executive Offices 50 Northern Avenue, Boston, MA 02210 Item 2. (a) Name of Person Filing Capital World Investors (b) Address of Principal Business Office or, if None, Residence 333 SOUTH HOPE STREET, 55TH FLOOR, LOS ANGELES, CALIFORNIA 90071 (c) Citizenship N/A (d) Title of Class of Securities Common Stock (e) CUSIP Number 92532F100 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) [ ] Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o). (b) [ ] Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c). (c) [ ] Insurance Company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c). (d) [ ] Investment Company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) [X] An investment adviser in accordance with Rule 240.13d-1(b)(1)(ii)(E); (f) [ ] An employee benefit plan or endowment fund in accordance with Rule 240.13d-1(b)(1)(ii)(F); (g) [ ] A parent holding company or control person in accordance with Rule 240.13d-1(b)(1)(ii)(G); (h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) [ ] A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) [ ] Group, in accordance with Rule 240.13d-1(b)(1)(ii)(J). Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount Beneficially Owned: 22,080,207 ** (b) Percent of Class: 8.6% (c) Number of shares as to which such person has: (i) sole power to vote or to direct the vote 22,009,491 (ii) shared power to vote or to direct the vote 0 (iii) sole power to dispose or to direct the disposition of 22,080,207 (iv) shared power to dispose or to direct the disposition of 0 **Capital World Investors ("CWI") is a division of Capital Research and Management Company ("CRMC"), as well as its investment management subsidiaries and affiliates Capital Bank and Trust Company, Capital International, Inc., Capital International Limited, Capital International Sarl, Capital International K.K., Capital Group Private Client Services, Inc., and Capital Group Investment Management Private Limited (together with CRMC, the "investment management entities"). CWI's divisions of each of the investment management entities collectively provide investment management services under the name "Capital World Investors." CWI is deemed to be the beneficial owner of 22,080,207 shares or 8.6% of the 257,683,184 shares believed to be outstanding. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five

View Full Filing

View this SC 13G/A filing on SEC EDGAR